Changes In Comorbid Diseases In Morbidly Obese Patients Treated By Laparoscopic Adjustable Gastric Banding

Abstract

Objectives: Morbid obesity is often accompanied by several comorbid diseases which reduce lifespan and impair quality of life. Laparoscopic adjustable gastric banding (LAGB) is a minimal invasive procedure effective in the treatment of morbid obesity. The aim of this study was to determine the change in comorbidities in patients treated by LAGB who achieved weight loss. Methodology: Among 134 morbidly obese patients treated by LAGB, 127 patients who were followed regularly and evaluated regarding the change in comorbidities, and laboratory and clinical measurements were recorded. Excess weight loss (EWL) and the percent improvement in comorbid diseases (PICD) were calculated by using the Friedman's test. P value of <0.05 was considered statistically significant. Results: Of 127 cases with a mean age of 29.51+/-6.7 years. Pre-operative BMI was 48.38+/-7.81 kg/m(2). Comorbid disease was present in 62 (48.8%) patients. The mean follow-up duration was 23.83+/-8.78 months. The EWL was 52.6% (p<0.05) and the PICD was 74.8% (p<0.05). Complications were noted in 34 patients (26.8%). Conclusions: LAGB is a minimally invasive procedure which is effective in the treatment of morbid obesity, and reduces the length of hospital stay. Comorbid diseases are significantly improved in patients who achieve weight loss by the LAGB procedure.